Proximagen is the drug discovery and development subsidiary of Upsher-Smith Laboratories, Inc., a U.S.-based, family-owned, fully-integrated pharmaceutical company whose mission is to deliver high-value, high-quality therapies and solutions that measurably improve patients’ lives. The Proximagen team have a long heritage of small molecule drug discovery in CNS, Pain and inflammation. Located in Cambridge, U.K., Proximagen integrated facility has has in-house capabilities in all core drug discovery disciplines, including:
- Medicinal chemistry
- In vitro and in vivo biology
- Drug metabolism and pharmacokinetics (DMPK)
As our molecules transition into development, our Upsher-Smith colleagues in Minneapolis, Minnesota provide expertise and resources in the areas of:
- Translational medicine, including clinical pharmacology, modeling and simulation.
- Chemistry, manufacturing, controls (CMC) and formulation.
- Regulatory Affairs and Clinical Operations.
Dr Jonathan SavidgeDirector, Europe and Business Development
Public Health England
Public Health England (PHE) exists to protect and improve the England's health and wellbeing, and reduce health inequalities. It is an operationally autonomous Executive Agency of the UK Department of Health with £4 billion total budget and 6000 staff (most of them with scientific/clinical background).
PHE has 35 active patent families (diagnostics, detection, drugs, therapies, vaccines) and approximately 100 trademarks for out-licensing and co-development. Five year corporate priorities are: Alcohol, AMR, Best start for every child, Dementia, Ebola, Obesity, Smoking & TB.